Pulmonary thromboembolism prevention

Pulmonary thromboembolism prevention refers to the prophylactic clinical management aimed at averting the formation and migration of blood clots into the pulmonary arterial bed This clinical state involves mitigating the risk of acute cardiopulmonary vascular occlusion, which most commonly originates from deep vein thrombosis of the lower extremities or pelvis governed by venous stasis, endothelial injury, and hypercoagulability Preventing this condition protects against life-threatening sequela...

Pulmonary thromboembolism prevention refers to the prophylactic clinical management aimed at averting the formation and migration of blood clots into the pulmonary arterial bed Prophylaxis is indicated in populations vulnerable to venous thromboembolic events, including hospitalized medical patients with acute illness or immobility, individuals undergoing major orthopedic or general surgery, and patients with active malignancy or inherited thrombophilias

This clinical state involves mitigating the risk of acute cardiopulmonary vascular occlusion, which most commonly originates from deep vein thrombosis of the lower extremities or pelvis governed by venous stasis, endothelial injury, and hypercoagulability Preventing this condition protects against life-threatening sequelae, notably ventilation-perfusion mismatch, acute hypoxemia, right ventricular overload, and obstructive shock

This clinical state involves mitigating the risk of acute cardiopulmonary vascular occlusion, which most commonly originates from deep vein thrombosis of the lower extremities or pelvis governed by venous stasis, endothelial injury, and hypercoagulability Preventing this condition protects against life-threatening sequelae, notably ventilation-perfusion mismatch, acute hypoxemia, right ventricular overload, and obstructive shock

Prophylaxis is indicated in populations vulnerable to venous thromboembolic events, including hospitalized medical patients with acute illness or immobility, individuals undergoing major orthopedic or general surgery, and patients with active malignancy or inherited thrombophilias